Yet do much less ... so much less!

摘要

In this issue of Blood, Shanmuganathan et al have presented a model that has redefined the frequency of molecular (polymerase chain reaction [PCR] for BCR-ABL) testing in patients discontinuing tyrosine kinase therapy for chronic myeloid leukemia (CML) as part of attempts at treatment-free remission (TFR). This is a less conservative, more feasible approach that should make safe discontinuation a reality for more patients.(1)